Browse Studies — Arctuva

Phase 3

A Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy and Safety of Nerandomilast Over at Least 52 Weeks in Patients With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (FIBRONEER-ACT)

This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they h…

Interstitial Lung Diseases

Estimated

~$10 – $7,500

Boehringer IngelheimNCT07540988

Phase 3

A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tis…

Familial Pulmonary FibrosisInterstitial Lung AbnormalitiesInterstitial Lung Diseases

Estimated

~$10 – $7,500

Boehringer IngelheimNCT07201922

Phase 2

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis

RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis

Systemic SclerosisSclerodermaInterstitial Lung Diseases

Estimated

~$10 – $7,500

Cabaletta BioNCT06328777

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data…

Interstitial Lung DiseasesIdiopathic Pulmonary FibrosisSarcoidosis+1 more

Estimated

~$10 – $750

University of ChicagoNCT00470327